Seeking Alpha

Prosensa slides, Sarepta rebounds from photo error sell-off

  • Shares of Prosensa (RNA) fall nearly 9% on the day.
  • Investors may be getting increasingly nervous about the prospects for drisapersen following dystrophin response data that some regarded as disappointing.
  • Predictably, shares of Sarepta Therapeutics (SRPT) moved in the exact opposite direction, rising 4.5%.
  • The two names have been negatively correlated of late as drisapersen is a competitor to SRPT's eteplirsen.
  • Strength in shares of SRPT may also be attributable to investors reentering the name following Monday's sell-off which was triggered by what looks to be a largely inconsequential photo publication error.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)